Citation Impact
Citing Papers
Salt-Sensitive Blood Pressure in Mice With Increased Expression of Aldosterone Synthase
2007 StandoutNobel
Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure
2000
Comparison of Two Aquaretic Drugs (Niravoline and OPC-31260) in Cirrhotic Rats with Ascites and Water Retention
1999
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
2005 Standout
Nitric Oxide as a Mediator of Hemodynamic Abnormalities and Sodium and Water Retention in Cirrhosis
1998
Acute kidney injury
2012 Standout
Biological Effects of C-type Natriuretic Peptide in Human Myofibroblastic Hepatic Stellate Cells
1999
Indocyanine Green Retention Test as a Noninvasive Marker of Portal Hypertension and Esophageal Varices in Compensated Liver Cirrhosis
2013
Hyponatremia Treatment Guidelines 2007: Expert Panel Recommendations
2007 Standout
Changes of Intestinal Functions in Liver Cirrhosis
2016 Standout
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
2003 Standout
Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis
2010
Burden of liver diseases in the world
2018 Standout
Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites
1997
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis
2001
Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites
1997
Updated Clinical Classification of Pulmonary Hypertension
2009 Standout
Vasoactive substances in the circulatory dysfunction of cirrhosis
2001
Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced Cirrhosis
2010
The sympathetic nervous system in liver disease
1998
Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial
2012
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
2006 Standout
The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough
2002
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis
2004
Portal hypertensive bleeding in cirrhosis
2016 Standout
Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension
2002
Cardiorenal Syndrome
2008 Standout
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Plasma endotoxin and tumor necrosis factor-α in the hyperkinetic state of cirrhosis
1995
Molecular Mechanisms of Myocardial Remodeling. The Role of Aldosterone
2002
Updated Clinical Classification of Pulmonary Hypertension
2013 Standout
Acute and long-term effects of inhaled iloprost in portopulmonary hypertension
2010
Aquaretic effects of niravoline, a κ-opioid agonist, in patients with cirrhosis
2000
Pulmonary vascular disorders in portal hypertension
1998
Drugs targeting the renin–angiotensin–aldosterone system
2002
International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
2006
Pyroptosis: A new frontier in cancer
2019 Standout
Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
2013 Standout
Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis
2010
The molecular logic of endocannabinoid signalling
2003 Standout
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist
2007
A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis
2004
Platelet-activating factor in liver injury: A relational scope
2006
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
2014 Standout
Antifibrotic and Hemodynamic Effects of the Early and Chronic Administration of Octreotide in Two Models of Liver Fibrosis in Rats
1998
Systemic, Renal, and Hepatic Hemodynamic Derangement in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
2003
The inflammatory response in myocardial injury, repair, and remodelling
2014 Standout
Effect of salvia miltiorrhiza on left ventricular hypertrophy and cardiac aldosterone in spontaneously hypertensive rats
2002
Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre‐ or post‐treatment with glibenclamide
1999
Aldosterone and end-organ damage
2005
Cardiovascular Effects of Aldosterone and Post–Acute Myocardial Infarction Pathophysiology
2006
Synthesis of platelet-activating factor and its receptor expression in Kupffer cells in rat carbon tetrachloride-induced cirrhosis
2008
Obstructive sleep apnoea and its cardiovascular consequences
2008 Standout
Modification of cardiac function in cirrhotic patients with and without ascites
2000
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease
2002
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency
2006
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
Animal models of acute lung injury
2008 Standout
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
Systemic and portal hemodynamic effects of anandamide
2001
Aldosterone: Direct Effects on and Production by the Heart
2003
Homeostatic Responses in the Adrenal Cortex to the Absence of Aldosterone in Mice
2005 StandoutNobel
Cardiovascular effects of Danshen
2007 Standout
Guanylyl Cyclases and Signaling by Cyclic GMP
2000 Standout
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
2007
Brown Adipose Tissue: Function and Physiological Significance
2004 Standout
Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions
2005 Standout
Eplerenone
2003
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Of mice and models: improved animal models for biomedical research
2002
Tumor necrosis factor α mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity
2000
Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model
2009
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Aldosterone and end-organ damage
2007
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Works of Stéphane Cailmail being referenced
Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis
1994
Evidence for Normal Nitric Oxide—Mediated Vasodilator Tone in Conscious Rats With Cirrhosis
1992
Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats
1992
Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis
1996
Role of sympathetic cardiovascular tone in control of arterial pressure in rats with cirrhosis
1996
Cardiac aldosterone production and ventricular remodeling
2000
Altered growth and lack of responsiveness to angiotensin II in aortic vascular smooth muscle cells from cirrhotic rats
1997
Beneficial hemodynamic effects of bosentan, a mixed ETA and ETB receptor antagonist, in portal hypertensive rats
1998
Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats
1991
Relationship between hepatic blood flow, liver tests, haemodynamic values and clinical characteristics in patients with chronic liver disease*
1997
Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol
1993
Dose‐dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats
1996
Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis
1995
Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselectiveβ-blocker
1996
Haemodynamic and hormonal responses to long-term inhibition of nitric oxide synthesis in rats with portal hypertension
1996
Acute Haemodynamic Responses and Inhibition of Tumour Necrosis Factor-α by Pentoxifylline in Rats with Cirrhosis
1996
Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes
2002
Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis
1994
Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension
1993